Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003

Summary

This is a Phase 1, First-in-Human study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of PYC-003 in healthy adult participants and adult participants with confirmed PKD1 mutation-associated Autosomal Dominant Polycystic Kidney Disease (ADPKD) There are 4 parts in this study, i.e. Part A, Part B, Part C and Part D.

Timeline

Start

2025-04-07

Primary completion

2028-11

Completion

2028-11

Drugs

Indications